New injection aims to save Insulin-Making cells in type 1 diabetes
NCT ID NCT06964087
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called OPT101 in adults diagnosed with type 1 diabetes within the last 20 years. Participants receive injections three times a week for up to one year. The goal is to see if OPT101 can safely help the body keep making its own insulin, reducing the need for injected insulin. The trial involves 72 people and compares different doses to a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE I DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barbara Davis Center - University of Colorado Anschuttz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
-
Diablo Clinical Research Center
RECRUITINGWalnut Creek, California, 94598, United States
-
Rainier Clinical Research Center
RECRUITINGRenton, Washington, 98057, United States
-
University of Alabama at Birmingham - Department of Medicina
RECRUITINGBirmingham, Alabama, 35294, United States
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.